DXR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Daxor Corp (DXR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive analyst coverage and potential in the MedTech space, the lack of clear technical signals, absence of recent trading trends, and no significant financial data make it prudent to hold off on investing until more favorable conditions or data emerge.
The MACD is below 0 and negatively expanding, indicating bearish momentum. The RSI is at 33.89, which is neutral and does not suggest an oversold or overbought condition. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 11.929, with resistance at 12.724.
Analyst coverage initiated by Lake Street with a Buy rating and a $23 price target, highlighting Daxor as a high-growth MedTech company with a multi-billion-dollar addressable market.
Market sentiment is negative due to Trump's tariff announcements, which have raised concerns about inflation and global growth. Technical indicators suggest bearish momentum. No significant trading trends from hedge funds or insiders.
No financial data available for analysis.
Lake Street initiated coverage with a Buy rating and a $23 price target, emphasizing Daxor's potential in the MedTech diagnostic space and noting the market's underestimation of its business fundamentals.
